Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3SBioSTU:83B -2.62%87 Return-on-Tangible-Equity is 90.43% as of Dec. 2025, which is 213% above its 10-year median of 28.92. GuruFocus rates STU:83B with a GF Score™ of 87/100 and a GF Value™ of €1.40 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 1,199 Biotechnology companies, 3SBio ranks better than 96% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. 3SBio's annualized net income for the quarter that ended in Dec. 2025 was €1,728 Mil. 3SBio's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €1,910 Mil. Therefore, 3SBio's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 90.43%.
The historical rank and industry rank for 3SBio's Return-on-Tangible-Equity or its related term are showing as below:
STU:83B'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 19.81 Med: 28.92 Max: 141.54
Current: 62.53
During the past 12 years, 3SBio's highest Return-on-Tangible-Equity was 141.54%. The lowest was 19.81%. And the median was 28.92%.
STU:83B's Return-on-Tangible-Equity is ranked better than 96% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs STU:83B: 62.53
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
3SBio Return-on-Tangible-Equity Related Terms
3SBio Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for 3SBio's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:83B vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, 3SBio's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3SBio Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3SBio's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where 3SBio's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 90.43% mean?
3SBio (STU:83B) has a Return-on-Tangible-Equity of 90.43% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on 3SBio and its competitors. This is 213% above median its historical median of 28.92. Over the past decade, 3SBio's Return-on-Tangible-Equity has ranged from 19.81 to 141.54. According to the industry distribution chart, 3SBio ranks #48 out of 1199 companies in the Biotechnology industry, placing it in the top 4%.
Is 3SBio's Return-on-Tangible-Equity too high?
3SBio's current Return-on-Tangible-Equity of 90.43% is 213% above median its 10-year median of 28.92. Over the past 10 years, this metric has ranged from a low of 19.81 to a high of 141.54. Based on the distribution chart, 3SBio ranks #48 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 3SBio has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3SBio ranks #48 out of 1199 companies for Return-on-Tangible-Equity. This places 3SBio in the top 4% of its industry — outperforming the majority of peers. Historically, 3SBio's own Return-on-Tangible-Equity has ranged from 19.81 to 141.54 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on 3SBio and its competitors. 3SBio's current Return-on-Tangible-Equity is 90.43%, which is 213% above median its own 10-year median of 28.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (STU:83B) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.40, compared to a current price of €1.88 — trading 34% above its estimated fair value. The current Return-on-Tangible-Equity is 90.43%, which is 213% above median its 10-year median of 28.92. 3SBio's overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For 3SBio (STU:83B), the current Return-on-Tangible-Equity is 90.43% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3SBio (STU:83B) Overvalued in 2026?
Based on GuruFocus' analysis, 3SBio stock appears to be overvalued.
The current stock price of €1.88 is trading 34% above its estimated GF Value™ of €1.40.
GuruFocus considers 3SBio to be Modestly Overvalued.
Key valuation signals for STU:83B:
Return-on-Tangible-Equity: 90.43% (213% above median its 10-year median of 28.92)
GF Value™: €1.40 vs. price of €1.88 (34% above fair value)
No single metric tells the full story. See the STU:83B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
87GF Score
Get the complete analysis for STU:83B
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:83B has been successfully added to your 
